このエントリーをはてなブックマークに追加
ID 31860
JaLCDOI
FullText URL
Thumnail fulltext.pdf 14.2 MB
Author
Kaihara, Masanobu
Nakamura, Yoshio
Sugimoto, Taro
Uchida, Haruhito A.
Norii, Hisanao
Hanayama, Yoshihisa
Makino, Hirofumi
Abstract

We investigated the impact of olmesartan and temocapril on pancreatic islet beta-cells during the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. Four-week-old male OLETF rats were fed standard chow (untreated:n5), or chow containing either 0.005% olmesartan(n5) or 0.01% temocapril (n5) until being sacrificed at 35 weeks of age. Pancreas sections were double-stained with anti-insulin and anti-glucagon antibodies. The percent areas of beta-cells, alpha-cells and non-alpha-non-beta-cells were compared among groups. In untreated OLETF rats, the fasting plasma glucose (FPG) level was elevated at the 18th week and remained elevated until the 35th week. On the other hand, no significant elevation in FPG levels was observed in olmesartan- or temocapril-treated rats. Pancreatic islets from olmesartan-treated rats were significantly smaller in size as compared with those from untreated OLETF rats. Furthermore, the average area occupied by beta-cells as a fraction of the total area of an individual islet was significantly higher in olmesartan- or temocapril-treated rats than that in untreated OLETF rats. Olmesartan and temocapril both prevented the development of hyperglycemia, possibly through the prevention of islet beta-cell loss in spontaneously diabetic OLETF rats.

Keywords
angiotensin II type-1 receptor blocker
angiotensin converting enzyme inhibitor
pancreas
insulin secretion
Type 2 diabetes mellitus
Amo Type
Original Article
Published Date
2009-02
Publication Title
Acta Medica Okayama
Volume
volume63
Issue
issue1
Publisher
Okayama University Medical School
Start Page
35
End Page
42
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT